April 2014

CRT exclusive agreement:

Vertebrate Antibodies Ltd reached an agreement with Cancer Research Technology (CRT) to exclusively license a number of their monoclonal antibodies for Research Only.  The antibodies are specific towards the following human targets; BCLAF1, CCT2, CYP1A2, CYP1A, CYP2A6, CYP2E1, CYP2R1, CYP4F11, CYP4A11, CYP4V2, CYP4Z1, CYP3A4, CYP3A5, CYP3A7, CYP7B1, CYP8B1, CYP26A1, CYP26B1, CYP26C1, CYP39A1, CYP51A1, DRAM1, FANCM, LRAT, MMP1, MMP2, MMP3, MMP9, activated-MMP9, MTSS1, NSE, POT1, RYK,  SPRED1,  TIGAR, TIMP1 and TIMP2. (For more information see the link www.ximb.io)

CRT exclusive agreement:

The license includes 10 monoclonal antibodies (mAbs) towards Respiratory Syncytial (RS) virus. The antibodies have diagnostic and neutralising activities (see attachment). RS virus is a major cause of lower respiratory tract infection and is a major cause of lower respiratory tract infection during infancy. We believe that our antibodies are valuable research tools with significant diagnostic and therapeutic potential. We have mAbs that are specific to RS virus Group A and B (see attachment). We believe that many of the commercially available RS virus diagnostic kits can be improved to become clinically more useful by the inclusion of our antibodies, particularly mAb 4-14 which specifically recognises the phosphoprotein (VPP32) of RS virus Group B. Consequently, the use of this mAb will identify those patients infected with RS virus Group B. Furthermore, we have also produced mAbs with neutralising activities against RS virus; the latter recognise epitopes on the virus fusion protein. The mAb 11-3-A3, in particular, exhibits high in vitro neutralising activity (1000-fold reduction in infectious viral titre). We believe strongly that our antibodies have therapeutic potential to fight RS virus infections. (For more information see the link www.ximb.io)